Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Pipeline-Proof of Concept
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, granted with the Orphan Drug Designation by the European Medicines Agency and the US Food and Drug Administration, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Joan Negrescolor wins Junceda Award for G2B’s 5th anniversary illustrations

Junceda Award in the Advertising category, recognising the artistic work behind a visual narrative of…
Read more

Gate2Brain CEO Meritxell Teixidó Featured in the EIC’s Women Leading Innovation Campaign

The European Innovation Council (EIC) has featured Meritxell Teixidó, CEO and co-founder of Gate2Brain,…
Read more

Every milestone matters. Together, they shaped our journey.

Gate2Brain is celebrating its sixth anniversary, marking another milestone in a journey driven by science,…
Read more

Gate2Brain Selected for the EU Business Hub Mission at World Health Expo Osaka 2026

,
Gate2Brain has been selected to participate in the EU Business Hub Business Mission at World Health Expo…
Read more

Shilpa Biocare Invests in Gate2Brain to Advance G2B-002, an Innovative Brain Cancer Therapeutic Candidate

, , ,
Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment…
Read more

Gate2Brain Joins the EIC Women Leadership Programme

At Gate2Brain, we are pleased to share that our CEO, Meritxell Teixidó, has been selected to participate…
Read more

Mercedes Hurtado – Meet the Team

https://youtu.be/XD2W5vk-Nko
Read more

The future belongs to children: 3 startups that are changing their day to day

Three emerging companies promoted by Barcelona Activa offer a series of initiatives aimed at improving…
Read more

Gate2Brain’s CEO Highlighted Among 16 Women Entrepreneurs Shaping Future Technology

We are pleased to share that Meritxell Teixidó, CEO and co-founder of Gate2Brain, has been included…
Read more

Gate2Brain to Participate in the Barcelona Deep Tech Summit 2025

, ,
Gate2Brain will be participating in the Barcelona Deep Tech Summit 2025, a meeting point for companies,…
Read more
NEWS & MEDIA
1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social